MicroPhage receives $977,916 QTDP grant for development of MRSA/MSSA Blood Culture Test

MicroPhage, Inc. announced today that it has received two Qualifying Therapeutic Discovery Project (QTDP) grants totaling $977,916 from the IRS. The grants, awarded as part of the Affordable Care Act, apply to small-company R&D expenditures that reduce the cost and increase the quality of healthcare in the U.S. The grants will be applied to the development of MicroPhage's first product, the MRSA/MSSA Blood Culture Test, currently under review at the FDA.

“Armed with this information, doctors will be able to save lives and reduce the healthcare costs that are incurred by treating infections with the wrong antimicrobials.”

Hospital-acquired bacterial infections currently kill over 100,000 Americans each year, including 20,000 deaths attributed to the MRSA "superbug." Up to half of these infections are initially treated with the wrong antibiotics.

"Our technology will aid in the rapid determination of antimicrobial treatment for patients with bacterial infections," said Drew Smith, Chief Science Officer at MicroPhage. "Armed with this information, doctors will be able to save lives and reduce the healthcare costs that are incurred by treating infections with the wrong antimicrobials." 

SOURCE MicroPhage, Inc.